Filing Flows › Kymera Therapeutics (KYMR) › Q1 2026 › vs Q1 2025
Kymera Therapeutics (KYMR) Q1 2026 vs Q1 2025 (year over year)
Kymera Therapeutics's revenue rose $12.3M (+55%) from $22.1M in Q1 2025 to $34.4M in Q1 2026.
Kymera Therapeutics, Q1 2026: revenue $34.4M (+56% year over year), operating margin -244.9%, net loss $69.2M, operating cash flow −$88.8M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $34.4M | $22.1M | $12.3M | +55% |
| Other income, net | $14.9M | $8.8M | $6.1M | +69% |
| Net loss | $69.2M | $65.6M | $3.7M | +6% |
| Costs & expenses | $119M | $96.5M | $22.0M | +23% |
| Operating costs | $119M | $96.5M | $22.0M | +23% |
| Operating cash sources | $107M | $95.4M | $11.4M | +12% |
| Depreciation & amortization | $2.0M | $2.0M | −$26K | -1% |
| Share-based compensation | $16.0M | $14.2M | $1.8M | +12% |
| Cash used in operations | $88.8M | $79.2M | $9.7M | +12% |
| Net loss absorbed | $69.2M | $65.6M | $3.7M | +6% |
| Working capital & other | $37.6M | $29.9M | $7.8M | +26% |
Questions
How much did Kymera Therapeutics's revenue grow year over year in Q1 2026?
Kymera Therapeutics's revenue rose $12.3M (+55%) from $22.1M in Q1 2025 to $34.4M in Q1 2026.